Spin off companies

Although this is by no means expected from ICREA researchers, it so happens that sometimes they hit on something that shows promise of becoming a powerful new technology, but it seems impossible to develop that further without significant investment of time and money. In these cases, many choose to explore the option of creating a spin-off company dedicated to the concept.

List of spin off companies

  • PEPTOMYC

    Jointly supported by the Vall d’Hebron Institut d’Oncologia (VHIO) and ICREA.
    Entrepreneur: ICREA Research Professor Laura Soucek.
    Born in December 2014.

    view details

    Peptomyc SL is a company focused on the
    development of a new generation of cell
    penetrating peptides (CPPs) for cancer
    treatment. The company was founded in
    December 2014 and it is based on Dr. Soucek’s
    scientific work focused on Myc inhibition.

    Background and market opportunity

    Chemotherapy is currently the most common
    non-surgical therapeutic option for the majority
    of cancers. Unfortunately, it often results in poor
    overall outcome for the patients due to the
    development of resistance to these nonselective
    treatments. Currently the alternative to
    such therapies is so-called “personalized
    medicine”, but very few targeted therapies have
    been commercialized to date and these target a
    restricted subset of cancers. In addition, the
    majority of these therapies target degenerate
    and redundant functions in tumor cells, resulting
    once again in resistance to treatment. Myc is an
    oncogene causally implicated in most cancers
    and is often associated with aggressive, poorly
    differentiated and angiogenic tumors. Myc has a
    non-redundant function in cancer around which
    tumors cannot evolve, hence targeting Myc is the
    most promising therapeutic opportunity we
    have to date. However, a Myc inhibitor has yet to
    become clinically available.

    Technology

    Dr. Laura Soucek has generated Omomyc, a
    dominant-negative Myc mutant that is able to
    prevent Myc-dependent gene transactivation
    functions both in vitro and in vivo, negating
    Myc’s ability to bind its DNA recognition binding
    site. Omomyc has proven to be the most
    efficacious direct Myc inhibitor to date and
    appears to be therapeutically valuable in a
    variety, if not all, cancer types, but so far it has
    only been considered a proof of principle, whose
    application could be limited to gene therapy.
    However, our new results indicate that the
    Omomyc peptide itself displays excellent cell
    penetrating properties and can efficiently enter
    cells and exert a strong anti-Myc activity that
    results in arrest/death of all cancer cell lines
    tested so far. Peptomyc SL now aims to further
    develop the Omomyc peptide - and improved
    variants - into clinically viable therapeutics for
    the treatment of cancer patients.

  • Pulmobiotics Logo
    Pulmobiotics SL

    Supported by the Centre de Regulació Genòmica and ICREA.
    Entrepreneur: ICREA Research Professor Luis Serrano
    Born in March 2020.

    view details
    CLOSE

    Pulmobiotics SL

    More than 1 billion persons suffer from chronic respiratory conditions worldwide, including 235 million people suffering from asthma and more than 200 million people enduring chronic obstructive pulmonary disease (COPD) which is moderate to severe in 65 million. 8.7 million people develop tuberculosis annually and more than 50 million people struggle with occupational lung diseases. Respiratory diseases are also among the leading causes of death worldwide, with 3.5 million deaths being attributed to lower respiratory diseases, 3.3 million to COPD and 1.4 million to tracheal, bronchial or lung cancer.

    Building on over 10 years of research funded with over 14m € by Spanish and EU grant agencies (details here), we have developed a proprietary microbial engineering and synthetic biology toolbox that underpins a novel live biotherapeutics platform. Pulmobiotics will use its technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.

  • QURV Technologies SL

    Supported by the Institut de Ciències Fotòniques (ICFO) and ICREA.
    Entrepreneur: ICREA Research Professor Gerasimos Konstantatos and Frank Koppens
    Born in July 2020.

    view details
    CLOSE

    QURV Technologies SL

    Qurv develops wide-spectrum image sensor technologies and integrated solutions to enable next-gen computer vision applications, addressing the expanding needs of an autonomous and intelligent new world.

    In the past, vision technologies were developed by capturing pictures from the type of information that can be detected by the human eye- ‘pretty’ pictures. With the emergence of powerful data science techniques, traditional imaging is shifting towards advanced sensing that unlocks new unprecedented capabilities destined to impact our society.

    Qurv's technology leverages current CMOS scalable manufacturing and advanced materials to unlock new levels of performance, reliability and function in XR devices, service robots and automotive.

  • QUSIDE

    Supported by the Institut de Ciències Fotòniques (ICFO) and ICREA.
    Entrepeneurs:  ICREA Research Professors Morgan Mitchell and Valerio Pruneri
    Formalised in September 2017.

    view details

    QuSide Technologies S.L. is set up to develop quantum technologies for the cyber-security and super-computation worlds. By exploiting photonics technologies and by leveraging the maturity of the semiconductor manufacturing industry, QuSide products bring unprecedented security and performance to the information era.

  • RADIANTIS

    Jointly supported by the Institut de Ciències Fotòniques (ICFO) and ICREA.
    Entrepreneur: ICREA Research Professor Majid Ebrahim Zadeh.
    Born in July 2005.

    view details

    Radiantis is a specialist manufacturer of
    advanced wavelength conversion technology for
    the laser and photonics market. Founded in
    2005 as a spin-off company from the research
    laboratory of Professor Majid Ebrahim-Zadeh at
    ICFO in Barcelona, the company is now
    established as a leading supplier of state-of-theart
    ultrafast optical parametric oscillators (OPOs)
    and harmonic wavelength generation systems in
    the world, with best-in-class performance in the
    sector. The products offered by Radiantis
    provide uniquely versatile laser light tools for a
    variety of scientific and technological
    applications in biophotonics, nanophotonics,
    optical microscopy and imaging, time-resolved
    spectroscopy, semiconductor research,
    frequency synthesis, comb generation, quantum
    optics, and surface science. The products are
    designed and developed with the highest
    technological standards, and focus on delivering
    maximum flexibility, functionality, and utility for
    end-users. As such, substantial effort is
    dedicated to transform laboratory prototypes to
    highly engineered, fully automated, and
    computer-controlled systems for maximum
    reliability, stability, and ease-of-use. The turnkey
    systems manufactured by Radiantis are capable
    of reaching difficult spectral regions from the UV
    to the mid-IR, not available to lasers. The
    company is now established as a certified
    supplier of frequency conversion systems to one
    of the largest suppliers of laser technology in
    the world, Newport/Spectra-Physics, USA. (www.
    newport.com).

    The flagship products manufactured by Radiantis
    are the uniquely versatile, hands-free
    femtosecond OPOs–InspireTM OPO Series–with
    an unprecedented gap-free wavelength
    coverage from the UV to near-IR (340-2500 nm),
    and a sealed cutting-edge femtosecond OPO–
    ORIA® IR–with full automation and interventionfree
    operation, providing continuous tuning
    across 1000–4500 nm in the near- to mid-IR. In
    2014, Radiantis further expanded its portfolio
    into instrumentation systems by introducing two
    new products to the market– a highly versatile
    compact spectrometer, and a laser beam
    stabilization module. The company has also
    established effective sales and distribution
    channels in Europe and Asia, and is actively
    involved in several collaborations with other
    leading manufacturers of laser technology
    worldwide, with the goal of developing new
    innovative products, strengthening its market
    position and consolidating its growth. Radiantis
    also participates in various national and
    European collaborative projects aimed at the
    development and commercialization of
    emerging and future technologies. Today,
    Radiantis is well integrated in the academic and
    research community and has a broad network of
    satisfied scientists deploying its advanced
    products across the world. The mission of the
    company is to maintain a leading position at the
    forefront of photonics technology worldwide by
    providing cutting-edge products with
    unsurpassed performance through continuous
    innovation.
    www.radiantis.com